Clinical trial · Interventional
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma
NCT00096837CI-TRIAL-00000350completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Motexafin Gadolinium Injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Rate of complete response, partial response and stable disease (clinical benefit rate)
Secondary outcomes (2)
- measure
- Progression-free survival
- measure
- Safety and tolerability
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Relapsed or Refractory Multiple Myeloma * ≥ 18 years old * Able to provide consent for participation * ECOG status 0-2 Lab values: * ANC ≥ 1,000/µL * WBC count ≥ 2.0/µL * Hemoglobin ≥ 8.0 g/dL * Platelet count ≥ 50,000/µL * AST and ALT ≤ 2 x ULN * Total Bilirubin ≤ 2 x ULN * Creatinine ≤ 2.0 mg/dL and * Not pregnant or lactating
References
Publications (0)
Data not yet available
No reference posted for this study.